- Home
- PBYI vs WALD Comparison
PBYI vs WALD Comparison
Compare PBYI & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | WALD |
|---|---|---|
| Founded | 2010 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 246.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PBYI | WALD |
|---|---|---|
| Price | $6.42 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $7.00 | $4.88 |
| AVG Volume (30 Days) | ★ 376.3K | 73.0K |
| Earning Date | 02-26-2026 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | $211,995,000.00 | ★ $274,560,000.00 |
| Revenue This Year | N/A | $4.61 |
| Revenue Next Year | N/A | $11.22 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | N/A | ★ 14.22 |
| 52 Week Low | $2.58 | $1.45 |
| 52 Week High | $6.30 | $4.10 |
Technical Indicators
Market Signals| Indicator | PBYI | WALD |
|---|---|---|
| Relative Strength Index (RSI) | 67.23 | 37.59 |
| Support Level | $6.05 | $1.45 |
| Resistance Level | $6.29 | $1.74 |
| Average True Range (ATR) | 0.25 | 0.14 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 96.25 | 28.45 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.